Cornell University researchers and collaborators have developed a neural implant so small that it can rest on a grain of salt ...
While fall is the season that mums pop up in garden shops, there's a better alternative: bright, colorful ornamental cabbage, ...
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...
Scientists at UC San Diego’s Scripps Institution of Oceanography have described a new way to produce large amounts of xanthommatin, a natural pigment, in a bacterium for the first time. Xanthommatin ...
Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
To truly deliver on their promise, nitrogen-fixing microbes need to up their game, says Ginkgo ag bio head, Michael Miile.
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Ap ...
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...
Cornell researchers and collaborators have developed a neural implant so small that it can rest on a grain of salt, yet it can wirelessly transmit ...
Korea Ginseng Corp. said Monday it has launched G1899, a new premium brand for natural health ingredients, as part of efforts to expand its business-to-business ...
In October, the FDA granted platform technology designation to the genetically modified ... and review processes for drug product applications that incorporate designated platform technologies, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback